---
title: "Butorphanol for Pain Relief After Cesarean Section: A Retrospective Study"
nct_id: NCT07175363
overall_status: NOT_YET_RECRUITING
sponsor: "Sichuan Provincial People's Hospital"
study_type: OBSERVATIONAL
primary_condition: Caesarean Section
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07175363.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07175363"
ct_last_update_post_date: 2025-09-16
last_seen_at: "2026-05-12T07:25:35.484Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Butorphanol for Pain Relief After Cesarean Section: A Retrospective Study

**Official Title:** The Application of Butorphanol in Postoperative Analgesia Management After Cesarean Section: A Retrospective Cohort Study

**NCT ID:** [NCT07175363](https://clinicaltrials.gov/study/NCT07175363)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 2500
- **Lead Sponsor:** Sichuan Provincial People's Hospital
- **Conditions:** Caesarean Section
- **Start Date:** 2025-09-20
- **Completion Date:** 2026-06-30
- **CT.gov Last Update:** 2025-09-16

## Brief Summary

This study explored the association between postoperative functional recovery and the formula of analgesic pumps as well as other related factors (such as age, intraoperative blood loss, operation duration, etc.) by retrospectively analyzing the clinical data of patients undergoing cesarean section in the main campus and branches of Sichuan Provincial People's Hospital from September 2024 to June 2025. The value of this study lies in: 1) providing a basis for optimizing the postoperative analgesia plan after cesarean section. 2) To provide references for the formulation of personalized analgesia strategies in clinical practice, improve the postoperative recovery quality of patients, promote the concept of enhanced recovery after surgery, and reduce the medical burden.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Age 18-55 years
2. ASAI-III level
3. Scheduled or emergency cesarean section
4. Postoperative use of analgesic pump (formulation includes buprenorphine or tramadol or hydromorphone, etc.)
5. Complete electronic medical records

Exclusion Criteria:

1. Postoperative analgesia pump usage time is less than 24 hours
2. Missing key information such as follow-up status in medical records
```

## Arms

- **The group using the analgesic pump**

## Interventions

- **An postoperative analgesic pump was used** (DRUG) — The drugs in the analgesic pump include butorphanol, hydromorphone, tramadol, and other medications.

## Primary Outcomes

- **Pain Score** _(time frame: 2 days post-surgery)_ — The Visual Analog Scale (VAS) is primarily used, where 1 represents no pain (best outcome) and 10 represents the worst pain (worst outcome); other scales may be used if necessary.
- **Postoperative functional recovery status** _(time frame: 2 days post-surgery)_ — Postoperative functional recovery status mainly includes: the time of first passage of gas, the time of first ambulation, the time of first catheter removal, and the recovery of limb muscle strength. The passage of gas, ambulation, and catheter removal times are self-reported by the patients, recording the days after surgery when the events occurred. The recovery of limb muscle strength is classified into six levels, ranging from 0 to 5, where 0 indicates no detectable muscle contraction (worst outcome) and 5 indicates normal muscle strength (best outcome).
- **Sedation score** _(time frame: 2 days post-surgery)_ — The sedation score uses a scale from -5 to +4, where -5 is defined as coma (one of the worst outcomes); -4 is defined as severe sedation (responds to physical stimulation); -3 is moderate sedation (no response to auditory stimulation); -2 is mild sedation (unable to maintain alertness for more than 10 seconds); -1 is drowsiness (not fully awake but can stay awake for more than 10 seconds); 0 is the awake natural state (best outcome); +1 is restlessness and anxiety (anxious and tense, but only slight body movement); +2 is agitation and anxiety (intense body movement); +3 is very agitated (trying to remove body tubes); +4 is aggressive (violent behavior) (one of the worst outcomes).

## Secondary Outcomes

- **Overall patient satisfaction rating** _(time frame: 2 days post-surgery)_
- **Nausea and vomiting** _(time frame: 2 days post-surgery)_
- **Adverse reactions** _(time frame: 2 days post-surgery)_

## Recent Field Changes (last 30 days)

- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07175363.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07175363*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*